期刊文献+

Mst1-YAP2信号通路在肥厚性心肌病中分子机制及作用的研究现状 被引量:5

下载PDF
导出
摘要 肥厚性心肌病(Hypertrophic cardiomyopathy,HCM)是一种以心肌非对称性肥厚和心室(一般指左心室)内腔变小为特征的心肌细胞增生性疾病,是一种常见(成人发生率1/500)、异质性突出的心血管疾病。HCM的临床表现多样,可无症状或轻度胸闷、胸痛、心悸,并发心房颤动、室性心律失常、心力衰竭(心衰)及心源性猝死等。近几年,随着分子生物学研究的深入发展,蛋白信号转导通路逐渐成为肥厚性心肌病临床研究和实验心脏病学的热门研究课题。国内外研究证实,Mst信号通路在细胞增殖与凋亡过程中发挥重要的基因调控作用,对于组织增生,器官大小具有极其重要的研究意义,为HCM致病机理的探索提供了新的思路,为远期HCM的治疗提供了新的治疗靶点。本文就Mst信号通路的发现、分子机制及其在肥厚性心肌病中的潜在作用进行简要概述。
作者 刘冬 来永强
出处 《心肺血管病杂志》 CAS 2012年第5期633-635,共3页 Journal of Cardiovascular and Pulmonary Diseases
  • 相关文献

参考文献24

  • 1童晓明,金景澍,王树春.肥厚性心肌病的研究新进展[J].心肺血管病杂志,2000,19(1):74-77. 被引量:15
  • 2Pan D. Department of molecular biology and genetics, howd hughes medical institute, Johns Hopkins university school of medicine, baltimore, MD 21205, USA. The Hippo signaling pathway in development and cancer. Dev Cell, 2010,19 : 491- 505.
  • 3Andersen PS, Havndrup O, Hangs L, et al. Diagnostic yield, in- terpretation, and clinical utility of mutation screening of sareomere encoding genes in Danish hypertrophic eardiomyopathy patients and relatives. Hum Mutat,2009,30:363-370.
  • 4宋邦荣,来永强.肥厚型心肌病的相关基因学研究进展[J].心肺血管病杂志,2011,30(6):552-554. 被引量:11
  • 5Matsui Y, Nakano N, Shao D, et al. Lats2 is a negative regula- tor of myocyte size in the heart. Circ Res,2008 ,103 :1309-1318.
  • 6Scheel H, HofmanLn K. A novel interaction motif, SARAH, connects three classes of tumor suppressor. Curr Biol, 2003,13 : R899 -900.
  • 7Callus BA, Verhagen AM, Vaux DL. Association of mammalian sterile twenty kinases, Mstl and Mst2, with hSalvador via C-ter- minal coiled-coil domains, leads to its stabilization and phospho- rylation. FEBS J, 2006,273:4264-76.
  • 8Lehtinen MK, Bonni A. Demystifying MST Family Kinases in cell death. Bentham Science Publishers ,2008,8:313-318.
  • 9Zhao B, Li L, Lei Q, et al. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev, 2010, 24: 862-874.
  • 10Justice RW, Zilian O, Woods DF, et al. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dys- trophy kinase and is required for the comrol of cell shape and pro- liferation. Genes Dev, 1995, 9:534-546.

二级参考文献21

  • 1高明明.肥厚型心肌病的遗传学研究进展[J].心肺血管病杂志,1995,14(1):61-62. 被引量:2
  • 2贺峰,汪家瑞.磁共振成像检测心脏功能研究的进展[J].中华内科杂志,1996,35(3):200-202. 被引量:3
  • 3廖玉华.从心肌病病因学研究走向临床诊断与治疗实践[J].中华心血管病杂志,2007,35(1):1-2. 被引量:26
  • 4Ho CY,Seidman CE.A contemporary approach to hypertrophic cardiomyopathy.Circulation,2006,1 1 3:e858-862.
  • 5Knollmann BC,Chopra N,Hlaing T,et al.Casq2 deletion causes sarcoplasmic reticulum volume increase,premature Ca2 + release,and catecholaminergic polymorphic ventricular tachycardia.J Clin Invest,2006,116:2510-2520.
  • 6Elliott K,Watkins H,Redwood CS.Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy.J Biol Chem,2000,275:22069-22074.
  • 7Morner S,Richard P,Kazzam E,et al.Deletion in the cardiac troponin I gene in a family from northern Sweden with hypertophic cardiomyopathy.J Mol Cell Cardiol,2000,32:521-525.
  • 8Tsoutsman T,Chung J,Doolan A,et al.Molecular insights from a novel cardiac troponin I muse model of familial hypertrophic cardiomyopathy.J Mol Cell Cardiol,2006,41:623-632.
  • 9Anan R,Shono H,Kisanuki A,et al.Patients with familial bypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis.Circulation,1998,98:391-397.
  • 10Niimura H,Bachinski LL,Sangwatanaroj S,et al.Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.N Engl J Med,1998,338:1248-1257.

共引文献23

同被引文献39

  • 1魏熙胤,牛瑞芳.流式细胞仪的发展历史及其原理和应用进展[J].现代仪器,2006,12(4):8-11. 被引量:40
  • 2Bin Zhao, Li l,i, Qunying Lei, et al. The Hippo-YAP pathway in organ size control and tumorigenesis and updated version. Genes Dev, 2010, 24:862-874.
  • 3Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: New con- nections between regulation of organ size and cancer. Curr Opin Cell Biul, 2008, 20: 638-646.
  • 4Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth eontrol. Genes & Dev, 2007, 21 : 2747-2761.
  • 5Radu M, Chernqff J. The DeMSTification of mammalian Ste20 kinases. Curr Bio, 2009, 19 : R421-425.
  • 6Song H, Mak KK, Topoi L,et aI. Mammalian Mstl and Mst2 ki- nases play essential roles in organ size contrnl and tumor suppres- sion. Proc Natl Acad Sci, 2010, 107: 1431-1436.
  • 7Densham RM, O'Neill E, Munro J, et al. MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stressactivated kinase to regulate p21Wafl/Cipl stability. Mol Cell Biol 2009, 29 : 6380-6390.
  • 8Chan EH, Nousiainen M, Chalamalasetty RB, et al. The Ste20- like kinase Mst2 activates the human large tumor suppressor ki- nase Latsl. Oncogene, 2005, 24: 2076-2086.
  • 9Zhou D, Conrad C, Xia F, et al. Mstl and Mst2 maintain hepa- tocyte quiescence and suppress hepatoceltular carcinoma develop- ment through inactivation of the YAP1 oneogene. Cancer Cell, 2009, 16: 425-438.
  • 10Lu L, Li Y, Kim SM, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci, 2010, 107 : 1437-1442.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部